Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan
Shintaro Akiyama, Kaoru Yokoyama, Soichi Yagi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 11, pp. 1413-1424
Closed Access | Times Cited: 12

Showing 12 citing articles:

Continuous Treatment with Tofacitinib but Not Filgotinib Is Effective in Non-Responders with Active Ulcerative Colitis: A Propensity Score-Matching Analysis
Soichi Yagi, Hirokazu Fukui, Maiko Ikenouchi, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 1, pp. 217-217
Open Access | Times Cited: 1
Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment—insights from Phase II and III trials
Sara Massironi, Federica Furfaro, Sarah Bencardino, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 9, pp. 761-787
Open Access | Times Cited: 7
Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan
Shintaro Akiyama, Hiromichi Shimizu, Akiko Tamura, et al.
Alimentary Pharmacology & Therapeutics (2024)
Closed Access | Times Cited: 4
Editorial: Individualising JAK Inhibitor Selection for Patients With Ulcerative Colitis—Authors' Reply
Shintaro Akiyama, Toshimitsu Fujii
Alimentary Pharmacology & Therapeutics (2025)
Closed Access
Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
Shintaro Akiyama, Toshimitsu Fujii
Alimentary Pharmacology & Therapeutics (2025)
Open Access
Progressing advanced therapies for inflammatory bowel disease: Current status including dual biologic therapy and discontinuation of biologics
Kazuo Yashima, Hiroki Kurumi, Naoyuki Yamaguchi, et al.
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access
Filgotinib

Reactions Weekly (2025) Vol. 2047, Iss. 1, pp. 191-191
Closed Access
JAK inhibitor ameliorates inflammatory bowel disease in a patient with IKZF1 haploinsufficiency
Shota Inoue, M. Ikai, Ryusuke Nambu, et al.
Clinical Immunology (2025) Vol. 274, pp. 110470-110470
Closed Access
Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators
Yu Kyung Jun, Hyuk Yoon
Korean Journal of Gastroenterology (2024) Vol. 84, Iss. 2, pp. 51-64
Open Access | Times Cited: 1
Drug-Induced Acne in Inflammatory Bowel Disease: A Practical Guide for the Gastroenterologist
María José Temido, Sailish Honap, Anne Claire Bursztejn, et al.
The American Journal of Gastroenterology (2024)
Closed Access | Times Cited: 1
Real‐World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort Study
Akira Nogami, Kunio Asonuma, Shinji Okabayashi, et al.
United European Gastroenterology Journal (2024)
Open Access | Times Cited: 1
Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study
B Farkas, Talat Bessissow, Jimmy K. Limdi, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 24, pp. 7804-7804
Open Access | Times Cited: 1
Page 1

Scroll to top